Literature DB >> 31739941

Pediatric Cancer.

Sujith Baliga1, Torunn I Yock2.   

Abstract

In pediatric brain tumors, the intensification of chemotherapy has allowed for a reduction in radiotherapy (RT) volume to an involved field approach, particularly in patients with medulloblastoma. For patients with low-grade gliomas, the trend has remained to delay RT with chemotherapy; however, when RT is used, typically smaller clinical target volume margins are used. For patients with extracranial tumors, intensive chemotherapy to address systemic disease with local control is considered standard. Proton beam therapy shows significant promise in addressing both short-term and long-term toxicities in both central nervous system (CNS) and non-CNS pediatric tumors.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Pediatric cancer; Proton beam therapy; Survivorship

Mesh:

Year:  2019        PMID: 31739941     DOI: 10.1016/j.hoc.2019.08.021

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  3 in total

1.  Clinician's Commentary on Ospina and McNeely.

Authors:  Carolina Chamorro Viña
Journal:  Physiother Can       Date:  2020       Impact factor: 1.037

2.  Technology-Assisted Psychosocial Interventions for Childhood, Adolescent, and Young Adult Cancer Survivors: A Systematic Review and Meta-Analysis.

Authors:  Anao Zhang; Bradley Zebrack; Chiara Acquati; Michael Roth; Nina Jackson Levin; Kaipeng Wang; Samantha Schwartz
Journal:  J Adolesc Young Adult Oncol       Date:  2021-05-06       Impact factor: 2.223

3.  Combination Therapy With Anti-PD-1 or PD-1 Antibody Alone in Asian Pediatric Patients With Relapsed or Refractory Cancer.

Authors:  Yi Que; Juan Wang; Jia Zhu; Na Li; Junting Huang; Suying Lu; Feifei Sun; Lian Zhang; Zijun Zhen; Li Zhang; Ruiqing Cai; Haixia Guo; Xiaofei Sun; Yizhuo Zhang
Journal:  Front Immunol       Date:  2021-07-06       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.